Recent Updates
Recently added Catalysts
FATE Neutral Sentiment Score: 50/100

FT836, a Novel MICA/B-targeting CAR T-cell Therapy Engineered to Eliminate the Need for Conditioning Chemotherapy with Broad Activity Across Solid Tumor Indications

Key Takeaway: The article discusses FT836, a novel CAR T-cell therapy designed to target MICA/B and eliminate the need for conditioning chemotherapy. It aims to demonstrate broad activity across various solid tumor indications. However, specific details about its efficacy or clinical trial results are not provided in the text.
Price reaction · baseline $1.07 (2025-05-16 close) · hit pre-market · clean, no other FATE news in the window
day 0 close
+14%
day 1 · peak
+16.8%
day 3
+12.1%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Last updated: May 19, 2025